Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...

Home / News / Pearce IP Blog
Originally published in World Intellectual Property Review 3 2021 After surviving the Great Patent Cliff of 2011–2016,...
05 Oct 21 | EU | Celltrion announced that it has submitted a Marketing Authorisation Application to the EMA seeking...
27 Sep 21 | CA | Apobiologix announced that Health Canada has approved Bambevi® (biosimilar bevacizumab) in...
27 Sep 21 | Hikma Pharmaceuticals announced that it will acquire Custopharm for an initial cash consideration of USD...
18 Sep 21 | Merck announced that the first results from Ph III trials of Keytruda® (pembrolizumab) showed a...
New .au domain names will be available in Australia from 24 March 2022. From this date, individuals, businesses and...
13 Sep 21 | Samsung Bioepis reported on a five-year follow-up study comparing ONTRUZANT® (trastuzumab biosimilar) with...
02 Sep 21 | US | Amgen and Hospira appear ready to settle the ongoing dispute relating to Neupogen® (filgrastim). The...
A recent decision of Justice Burley in the Federal Court of Australia confirms that the bar for sufficiency and...
26 Aug 21 | US | Two former executives of JHL Biotech plead guilty to conspiracy to steal trade secrets and commit...
24 Aug 21 | UCB announced that it has gained EU marketing approval for Bimzelx® (bimekizumab), an IL-17A and IL-17F...
17 Aug 21 | US | The USPTO Patent Trial and Appeal Board (PTAB) will review Amgen’s US 8,273,707 Patent (related to...
05 Aug 21 | A new study reported that the safety profiles and pharmacokinetic parameters of Amgen’s ABP980 (biosimilar...
29 Jul 21 | US | The American Academy of Ophthalmology pushed back against insurance company pressure to use new...
27 Jul 21 | Abenza and BioXpress Therapeutics announced they have formed a new partnership to support biosimilar...
19 Jul 21 | Shanghai Henlius Biotech announced that the first patient has been dosed in its Ph I clinical trial of...